Tempest Therapeutics (NASDAQ:TPST) Issues Quarterly Earnings Results, Misses Estimates By $2.25 EPS

Tempest Therapeutics (NASDAQ:TPST) released its quarterly earnings data on Friday. The company reported ($2.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($2.25), FiscalAI reports.

Tempest Therapeutics Price Performance

NASDAQ TPST opened at $1.83 on Friday. The business’s fifty day moving average price is $1.94 and its 200-day moving average price is $3.35. The stock has a market capitalization of $26.24 million, a price-to-earnings ratio of -0.30 and a beta of -1.75. Tempest Therapeutics has a 1-year low of $1.50 and a 1-year high of $12.23.

Insider Buying and Selling at Tempest Therapeutics

In other news, CEO Matthew Angel purchased 231,482 shares of the stock in a transaction dated Tuesday, March 24th. The shares were purchased at an average cost of $2.16 per share, with a total value of $500,001.12. Following the acquisition, the chief executive officer directly owned 231,482 shares of the company’s stock, valued at $500,001.12. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 6.28% of the stock is owned by insiders.

Hedge Funds Weigh In On Tempest Therapeutics

An institutional investor recently bought a new position in Tempest Therapeutics stock. Dimensional Fund Advisors LP purchased a new stake in shares of Tempest Therapeutics, Inc. (NASDAQ:TPST) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 11,444 shares of the company’s stock, valued at approximately $33,000. Dimensional Fund Advisors LP owned 0.23% of Tempest Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 22.52% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on TPST shares. Zacks Research cut Tempest Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday. Wall Street Zen cut Tempest Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Reduce”.

Tempest Therapeutics Company Profile

Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.